Spravato® (Esketamine) Therapy
- Home
- Spravato® (Esketamine) Therapy
A New Option for Treatment-Resistant Depression
If you’ve tried multiple antidepressants without finding relief, Spravato® (esketamine) may offer a different path forward. Spravato® is an FDA-approved prescription nasal spray designed specifically for adults with treatment-resistant depression (TRD). Unlike traditional antidepressants, Spravato® works through a different pathway in the brain and may help improve depressive symptoms more rapidly.
What Is Spravato®?
Spravato® contains esketamine, a medication derived from ketamine. It is the first FDA-approved nasal spray treatment for adults with treatment-resistant depression and is administered under the supervision of a qualified healthcare provider in a certified treatment setting.
Spravato® may be appropriate for adults who:
- Have not responded adequately to at least two antidepressant medications
- Continue to experience persistent symptoms of depression
- Are seeking alternative treatment options under professional psychiatric care
What to Expect During Treatment
Your treatment journey begins with a comprehensive psychiatric evaluation to determine whether Spravato® is appropriate for your needs.
During a Treatment Session
Comprehensive psychiatric assessment
Personalized treatment planning
Administration of Spravato® nasal spray under medical supervision
Monitoring period following treatment
Ongoing follow-up and symptom assessment
Patients remain under observation after administration to ensure safety and comfort throughout the treatment process.
Why Choose Our Practice for Spravato® Therapy?
- Comprehensive psychiatric evaluations
- Personalized treatment plans
- Compassionate, patient-centered care
- Ongoing monitoring and support
- Evidence-based treatment approach
- Safe and professional clinical environment
Frequently Asked Questions About Spravato® (Esketamine) Therapy
Spravato® is an FDA-approved prescription nasal spray used in combination with an oral antidepressant for adults with treatment-resistant depression. It works differently than traditional antidepressants by targeting pathways in the brain associated with mood regulation.
Spravato® may be appropriate for adults who have tried two or more antidepressant medications without experiencing adequate symptom relief. A comprehensive psychiatric evaluation is required to determine eligibility.
Spravato® is administered as a nasal spray under the supervision of a qualified healthcare provider in a certified treatment setting. Patients are monitored following administration to ensure safety and comfort.
Treatment frequency varies depending on your individual needs and treatment response. Your provider will develop a personalized treatment plan and discuss the recommended schedule with you.
Traditional antidepressants primarily target serotonin, norepinephrine, or dopamine. Spravato® works through the glutamate system, offering a different treatment approach for individuals with treatment-resistant depression.
Every individual responds differently to treatment. Some patients may notice improvements earlier than with traditional antidepressants, while others may require ongoing treatment and monitoring to achieve optimal results.
No. Because Spravato® can cause temporary side effects such as dizziness, drowsiness, or changes in perception, patients should arrange transportation home after each treatment session.
Your appointment will include administration of the medication, monitoring by trained healthcare professionals, and an observation period to ensure your safety before leaving the treatment facility.
Some patients may experience temporary side effects such as dizziness, nausea, dissociation, increased blood pressure, headache, or sleepiness. Your provider will review potential risks and benefits before treatment begins.